Literature DB >> 25972504

Postexposure Prophylaxis Against Human Immunodeficiency Virus (HIV): New Guidelines From the WHO: A Perspective.

Jonathan E Kaplan1, Kenneth Dominguez2, Kebba Jobarteh1, Thomas J Spira1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25972504     DOI： 10.1093/cid/civ087

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  4 in total

1.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

2.  Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.

Authors:  Nadia Valin; Laurent Fonquernie; Anne Daguenel; Pauline Campa; Theresita Anthony; Marguerite Guiguet; Pierre Marie Girard; Marie Caroline Meyohas
Journal:  BMC Infect Dis       Date:  2016-11-29       Impact factor: 3.090

3.  Thematic synthesis HIV prevention qualitative studies in men who have sex with men (MSM).

Authors:  Augusto Mathias; Lorruan Alves Dos Santos; Alexandre Grangeiro; Marcia Thereza Couto
Journal:  Colomb Med (Cali)       Date:  2019-09-30

Review 4.  Learning from combination HIV prevention programmes to face COVID-19 emerging pandemic.

Authors:  Ricardo Palacios; Augusto Mathias
Journal:  Colomb Med (Cali)       Date:  2020-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.